Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1999 Feb;79(5-6):787–792. doi: 10.1038/sj.bjc.6690126

Busulphan is active against neuroblastoma and medulloblastoma xenografts in athymic mice at clinically achievable plasma drug concentrations

I Boland 1, G Vassal 1,2, J Morizet 1, M-J Terrier-Lacombe 3, D Valteau-Couanet 2, C Kalifa 2, O Hartmann 2, A Gouyette 1
PMCID: PMC2362679  PMID: 10070870

Abstract

High-dose busulphan-containing chemotherapy regimens have shown high response rates in children with relapsed or refractory neuroblastoma, Ewing's sarcoma and medulloblastoma. However, the anti-tumour activity of busulfan as a single agent remains to be defined, and this was evaluated in athymic mice bearing advanced stage subcutaneous paediatric solid tumour xenografts. Because busulphan is highly insoluble in water, the use of several vehicles for enteral and parenteral administration was first investigated in terms of pharmacokinetics and toxicity. The highest bioavailability was obtained with busulphan in DMSO administered i.p. When busulphan was suspended in carboxymethylcellulose and given orally or i.p., the bioavailability was poor. Then, in the therapeutic experiments, busulphan in DMSO was administered i.p. on days 0 and 4. At the maximum tolerated total dose (50 mg kg−1), busulphan induced a significant tumour growth delay, ranging from 12 to 34 days in the three neuroblastomas evaluated and in one out of three medulloblastomas. At a dose level above the maximum tolerated dose, busulphan induced complete and partial tumour regressions. Busulphan was inactive in a peripheral primitive neuroectodermal tumour (PNET) xenograft. When busulphan pharmacokinetics in mice and humans were considered, the estimated systemic exposure at the therapeutically active dose in mice (113 μg h ml−1) was close to the mean total systemic exposure in children receiving high-dose busulphan (102.4 μg h ml−1). In conclusion, busulphan displayed a significant anti-tumour activity in neuroblastoma and medulloblastoma xenografts at plasma drug concentrations which can be achieved clinically in children receiving high-dose busulphan-containing regimens. 1999 Cancer Research Campaign

Keywords: brain tumours, childhood cancer, bone marrow transplantation, pharmacokinetics

Full Text

The Full Text of this article is available as a PDF (87.6 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aaron R. H., Elion G. B., Colvin O. M., Graham M., Keir S., Bigner D. D., Friedman H. S. Busulfan therapy of central nervous system xenografts in athymic mice. Cancer Chemother Pharmacol. 1994;35(2):127–131. doi: 10.1007/BF00686634. [DOI] [PubMed] [Google Scholar]
  2. Arduino L. J., Mellinger G. T. Clinical trial of busulfan (NSC-750) in advanced carcinoma of prostate. Cancer Chemother Rep. 1967 Sep;51(5):295–303. [PubMed] [Google Scholar]
  3. Berger D. P., Winterhalter B. R., Dengler W. A., Fiebig H. H. Preclinical activity of hepsulfam and busulfan in solid human tumor xenografts and human bone marrow. Anticancer Drugs. 1992 Oct;3(5):531–539. doi: 10.1097/00001813-199210000-00014. [DOI] [PubMed] [Google Scholar]
  4. Bettan-Renaud L., Bayle C., Teyssier J. R., Benard J. Stability of phenotypic and genotypic traits during the establishment of a human neuroblastoma cell line, IGR-N-835. Int J Cancer. 1989 Sep 15;44(3):460–466. doi: 10.1002/ijc.2910440314. [DOI] [PubMed] [Google Scholar]
  5. Bhagwatwar H. P., Phadungpojna S., Chow D. S., Andersson B. S. Formulation and stability of busulfan for intravenous administration in high-dose chemotherapy. Cancer Chemother Pharmacol. 1996;37(5):401–408. doi: 10.1007/s002800050404. [DOI] [PubMed] [Google Scholar]
  6. Bhoopalam N., Price K. S., Norgello H., Fried W. Busulfan-induced suppression of natural killer cell activity. Exp Hematol. 1985 Dec;13(11):1127–1132. [PubMed] [Google Scholar]
  7. Bishop J. B., Wassom J. S. Toxicological review of busulfan (Myleran). Mutat Res. 1986 Jul;168(1):15–45. doi: 10.1016/0165-1110(86)90020-5. [DOI] [PubMed] [Google Scholar]
  8. Demirer T., Buckner C. D., Appelbaum F. R., Clift R., Storb R., Myerson D., Lilleby K., Rowley S., Bensinger W. I. High-dose busulfan and cyclophosphamide followed by autologous transplantation in patients with advanced breast cancer. Bone Marrow Transplant. 1996 May;17(5):769–774. [PubMed] [Google Scholar]
  9. Down J. D., Berman A. J., Warhol M., Van Dijken P. J., Ferrara J. L., Yeap B., Hellman S., Mauch P. M. Late tissue-specific toxicity of total body irradiation and busulfan in a murine bone marrow transplant model. Int J Radiat Oncol Biol Phys. 1989 Jul;17(1):109–116. doi: 10.1016/0360-3016(89)90377-5. [DOI] [PubMed] [Google Scholar]
  10. Dunn C. D. The chemical and biological properties of busulphan ("Myleran"). Exp Hematol. 1974;2(3):101–117. [PubMed] [Google Scholar]
  11. Dupuis-Girod S., Hartmann O., Benhamou E., Doz F., Mechinaud F., Bouffet E., Coze C., Kalifa C. Will high dose chemotherapy followed by autologous bone marrow transplantation supplant cranio-spinal irradiation in young children treated for medulloblastoma? J Neurooncol. 1996 Jan;27(1):87–98. doi: 10.1007/BF00146088. [DOI] [PubMed] [Google Scholar]
  12. Hartmann O., Benhamou E., Beaujean F., Pico J. L., Kalifa C., Patte C., Flamant F., Lemerle J. High-dose busulfan and cyclophosphamide with autologous bone marrow transplantation support in advanced malignancies in children: a phase II study. J Clin Oncol. 1986 Dec;4(12):1804–1810. doi: 10.1200/JCO.1986.4.12.1804. [DOI] [PubMed] [Google Scholar]
  13. Hassan M., Oberg G., Ericson K., Ehrsson H., Eriksson L., Ingvar M., Stone-Elander S., Thorell J. O., Smedmyr B., Warne N. In vivo distribution of [11C]-busulfan in cynomolgus monkey and in the brain of a human patient. Cancer Chemother Pharmacol. 1992;30(2):81–85. doi: 10.1007/BF00686397. [DOI] [PubMed] [Google Scholar]
  14. Josvasen N., Boyum A. Haematopoiesis in busulphan-treated mice. A comparison between two different stem cell assays. Scand J Haematol. 1973;11(1):78–86. doi: 10.1111/j.1600-0609.1973.tb00098.x. [DOI] [PubMed] [Google Scholar]
  15. Kalifa C., Hartmann O., Demeocq F., Vassal G., Couanet D., Terrier-Lacombe M. J., Valteau D., Brugieres L., Lemerle J. High-dose busulfan and thiotepa with autologous bone marrow transplantation in childhood malignant brain tumors: a phase II study. Bone Marrow Transplant. 1992 Apr;9(4):227–233. [PubMed] [Google Scholar]
  16. Mattern J., Bak M., Hahn E. W., Volm M. Human tumor xenografts as model for drug testing. Cancer Metastasis Rev. 1988 Nov;7(3):263–284. doi: 10.1007/BF00047755. [DOI] [PubMed] [Google Scholar]
  17. McCracken C. H., 3rd, Lottsfeldt J. L., Lee M. Y. Concurrent activation of granulocytes and osteoclasts in busulfan-suppressed bone marrow in response to transplantation of a mammary carcinoma in mice. Exp Hematol. 1988 May;16(4):285–289. [PubMed] [Google Scholar]
  18. Millar J. L., Hudspith B. N., Blackett N. M. Reduced lethality in mice receiving a combined dose of cyclophosphamide and busulphan. Br J Cancer. 1975 Aug;32(2):193–198. doi: 10.1038/bjc.1975.149. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. SULLIVAN R. D. Myleran therapy in bronchogenic carcinoma. Ann N Y Acad Sci. 1958 Apr 24;68(3):1038–1045. doi: 10.1111/j.1749-6632.1958.tb42662.x. [DOI] [PubMed] [Google Scholar]
  20. Samlowski W. E., Araneo B. A., Butler M. O., Fung M. C., Johnson H. M. Peripheral lymph node helper T-cell recovery after syngeneic bone marrow transplantation in mice prepared with either gamma-irradiation or busulfan. Blood. 1989 Sep;74(4):1436–1445. [PubMed] [Google Scholar]
  21. Tutschka P. J., Santon G. W. Bone marrow transplantation in the busulfin-treated rat. III. Relationship between myelosuppression and immunosuppression for conditioning bone marrow recipients. Transplantation. 1977 Jul;24(1):52–62. doi: 10.1097/00007890-197707000-00008. [DOI] [PubMed] [Google Scholar]
  22. Vassal G., Boland I., Santos A., Bissery M. C., Terrier-Lacombe M. J., Morizet J., Sainte-Rose C., Lellouch-Tubiana A., Kalifa C., Gouyette A. Potent therapeutic activity of irinotecan (CPT-11) and its schedule dependency in medulloblastoma xenografts in nude mice. Int J Cancer. 1997 Sep 26;73(1):156–163. doi: 10.1002/(sici)1097-0215(19970926)73:1<156::aid-ijc24>3.0.co;2-d. [DOI] [PubMed] [Google Scholar]
  23. Vassal G., Challine D., Koscielny S., Hartmann O., Deroussent A., Boland I., Valteau-Couanet D., Lemerle J., Lévi F., Gouyette A. Chronopharmacology of high-dose busulfan in children. Cancer Res. 1993 Apr 1;53(7):1534–1537. [PubMed] [Google Scholar]
  24. Vassal G., Deroussent A., Challine D., Hartmann O., Koscielny S., Valteau-Couanet D., Lemerle J., Gouyette A. Is 600 mg/m2 the appropriate dosage of busulfan in children undergoing bone marrow transplantation? Blood. 1992 May 1;79(9):2475–2479. [PubMed] [Google Scholar]
  25. Vassal G., Deroussent A., Hartmann O., Challine D., Benhamou E., Valteau-Couanet D., Brugières L., Kalifa C., Gouyette A., Lemerle J. Dose-dependent neurotoxicity of high-dose busulfan in children: a clinical and pharmacological study. Cancer Res. 1990 Oct 1;50(19):6203–6207. [PubMed] [Google Scholar]
  26. Vassal G., Re M., Gouyette A. Gas chromatographic-mass spectrometric assay for busulfan in biological fluids using a deuterated internal standard. J Chromatogr. 1988 Jul 15;428(2):357–361. doi: 10.1016/s0378-4347(00)83928-6. [DOI] [PubMed] [Google Scholar]
  27. Vassal G., Terrier-Lacombe M. J., Bissery M. C., Vénuat A. M., Gyergyay F., Bénard J., Morizet J., Boland I., Ardouin P., Bressac-de-Paillerets B. Therapeutic activity of CPT-11, a DNA-topoisomerase I inhibitor, against peripheral primitive neuroectodermal tumour and neuroblastoma xenografts. Br J Cancer. 1996 Aug;74(4):537–545. doi: 10.1038/bjc.1996.398. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Vassal G., Terrier-Lacombe M. J., Lellouch-Tubiana A., Valery C. A., Sainte-Rose C., Morizet J., Ardouin P., Riou G., Kalifa C., Gouyette A. Tumorigenicity of cerebellar primitive neuro-ectodermal tumors in athymic mice correlates with poor prognosis in children. Int J Cancer. 1996 Apr 22;69(2):146–151. doi: 10.1002/(SICI)1097-0215(19960422)69:2<146::AID-IJC14>3.0.CO;2-7. [DOI] [PubMed] [Google Scholar]
  29. Yeager A. M., Shinohara M., Shinn C. Hematopoietic cell transplantation after administration of high-dose busulfan in murine globoid cell leukodystrophy (the twitcher mouse). Pediatr Res. 1991 Mar;29(3):302–305. doi: 10.1203/00006450-199103000-00016. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES